None listed
Conditions
Brief summary
In previous studies the addition of zinc to standard therapy of hepatitis C induced limited benefits on viral response and some of these studies have reported improved transaminases with zinc therapy. It is important to notice that a group of the hepatitis C patients have beta thalassemia major as well and combination therapy with INF-a plus ribavirin should be suggested for them . Zinc depletion has been reported in patients with beta thalassemia major under treatment of chelator agents such as deferioxamine, deferiprone and deferasirox. Using of zinc accompanied with standard regimen may have a benefit in pharmacotherapy of chronic hepatitis C with beta thalassemia major.So the aim of present study was to evaluate the effect of zinc administration on viral response in patients with chronic hepatitis
Interventions
Addition of oral zinc(30 mg /d elemental) for 48 weeks to standard pharmacotherapy of hepatitis C (peg interferon alfa plus ribavirin) Duration of standard therapy will be 48 weeks too. In other words, peg interferon,ribavirin,zinc/placebo will be start with each other for 48 weeks.
adherence monitoring with tablet return
Sponsors
Shahid Beheshti University of Medical Sciences
Study design
Allocation
Randomised controlled trial
Primary purpose
Treatment
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
60 patients with recent diagnosis of chronic hepatitis C and previous diagnosis of beta thalassemia major
Exclusion criteria
hepatitis B and human immunodeficiency viruses infected, recieving zinc or any complement containing zinc
Outcome results
None listed